RANI

Rani Therapeutics Holdings, Inc. [RANI] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RANI Stock Summary

Top 10 Correlated ETFs

RANI

Top 10 Correlated Stocks

RANI

In the News

RANI Financial details

Company Rating
-
Market Cap
270.85M
Income
-33.97M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
140
Optionable
No
Shortable
Yes
Earnings
20 Mar 2024
P/E
-1.81
Forward P/E
-
PEG
0.36
P/S
-
P/B
4.57
P/C
-
P/FCF
-4.65
Quick Ratio
8.24
Current Ratio
8.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.33
EPS next Y
-
EPS next Q
-
EPS this Y
-50%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.3%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-25%
-
-
-
-
SMA20
-20%
SMA50
-58.82%
SMA100
-58.21%
Inst Own
-
Inst Trans
-
ROA
-63%
ROE
-162%
ROC
-1.11%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.82-5.79
52W High
-89.49%
52W Low
-47.47%
RSI
32.04
Rel Volume
3.72
Avg Volume
82.44K
Volume
307.01K
Perf Week
-6.18%
Perf Month
-50.91%
Perf Quarter
-60.5%
Perf Half Y
-71.76%
-
-
-
-
Beta
0.916
-
-
Volatility
0.02%, 0.16%
Prev Close
-6.28%
Price
0.5253
Change
-9.43%

Something similar

Top by Market Cap
BRH.DE
NVD.DE
GOOG
ABEC.DE
BRYN.DE
Top Correlated ETFs
AMZD
SSG
HIBS
BERZ
UVIX
Top Correlated Stocks
AVA
0I4W.L
8281.T
CPK
WTRG
Similar Market Cap
0VIK.L
BLUE.PA
XLUS.L
IMPEXFERRO.NS
RZR.TA

Company Profile

Healthcare Biotechnology
  • Volume Average 82.44K
  • Market Capitalization 270.85M
  • Employee 140
  • CEO Mr. Talat Imran
  • Headquarters San Jose,CA,US
  • IPO Date 2021-07-30
  • Website https://www.ranitherapeutics.com

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.